Siliphos® overview

Scientific support

As demonstrated by comparative pharmacokinetic studies, Silipide® represents the most absorbable oral form of silybin known.

In rats, after oral administration of 200 mg/kg of silybin, the plasma levels of silybin and its conjugated metabolites were below the analytical detection limit, while, after oral administration of Silipide® (200 mg/kg as silybin) the plasma levels of silybin (free and total) were easily measurable, being well absorbed within minutes when in phytosomal form(3).

Plasma levels of total silybin after oral Silipide® and silybin in rats, where Silipide® (200 mg/kg as silybin) and silybin (200 mg/kg) were administered by gavage as aqueous suspensions to 6 male rats

In another study on rats, the pharmacokinetic of Silipide® and silymarin were compared(4). Silybin given as Silipide®at 200 mg/kg was detectable in the plasma within minutes, peaked after 1 h, and its plasma levels remained elevated for over 6 hours. The AUC value of free silybin after Silipide® intake was more then 400% higher than after intake of silymarin. Silipide® was also shown to rapidly reach the liver, cross the liver cells, and appear in the bile within 2 h. The amount of silybin reaching the bile after Silipide® dosing was at least 6.5 times higher than that from non-complexed silybin administered as silymarin.

Mean plasma levels of unconjugated flavolignans after a single oral dosage of Silipide® and silymarin (both dosed at 200 mg/kg as silybin) in rats


Mean plasma levels of total flavolignans (silybin + isosilybin + silydianin + silychristin) after a single oral dosage of Silipide® and silymarin (both dosed at 200 mg/kg as silybin) in rats

The pharmacokinetics of Silipide® in healthy human subjects showed that complexation with phosphatidylcholine improved the oral bioavailability of silybin 4.6 fold compared with silymarin, presumably because of a facilitated passage across the gastrointestinal mucosa(5).

Expand Bibliography
  1. Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic actions of flavolignans from Silybum marianum fruits. Planta Med 1984;50:248–50.
  2. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001;15:465–89.
  3.  Morazzoni P, Magistretti MJ, Giachetti C, Zanolo G. Eur J Drug Metab Pharmacokinet 1992;17:39–44. 615.
  4.  Morazzoni P, Montalbetti A, Malandrino S, Pifferi G.. Eur J Drug Metab Pharmacokinet 1993;18:289–97. 
  5.  Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Eur J Drug Metab Pharmacokinet 1990;15:333–8.